Which tests are recommended prior to starting Rivaroxaban or Apixaban?

Rivaroxaban and Apixaban are direct oral anticoagulants (DOACs) commonly used for preventing thromboembolic events. Prior to initiating therapy with these medications, it is essential to assess the patient's renal function because both drugs are partially eliminated through the kidneys. Evaluating renal function helps to determine the appropriate dosing and ensures patient safety, as impaired renal function can lead to increased drug accumulation and a higher risk of bleeding.

Additionally, a complete blood count (CBC) is essential to evaluate the patient’s hemoglobin levels and platelet counts. This information is vital as it helps to identify any underlying bleeding disorders or anemia before starting anticoagulant therapy, minimizing the risk of potential complications associated with anticoagulation.

Tests like liver function, electrolyte panels, or lipid profiles may be important for other medication assessments or conditions but do not directly influence the initial management or safety profile of Rivaroxaban or Apixaban in the same way that renal function and CBC do. Therefore, assessing renal function and complete blood count is a crucial step in the safe initiation of treatment with these anticoagulants.